RBC Capital Reiterates Outperform on ADC Therapeutics, Maintains $6 Price Target

Benzinga Newsdesk www.benzinga.com Negative 79.7%

Neg 79.7% Neu 0% Pos 0%

RBC Capital analyst Leonid Timashev reiterates ADC Therapeutics (NYSE:ADCT) with a Outperform and maintains $6 price target.